Combination therapy partner

Providing new treatment options for patients

In October, 2022, we have entered into a clinical trial collaboration agreement with Merck on clinical study of combination therapy between Jacobio’s KRAS G12C inhibitor Glecirasib (JAB-21822) and Merck’s epidermal growth factor receptor (EGFR) inhibitor Erbitux® (cetuximab).

Click here to know more about our partnership.


In March, 2023, we have entered into a clinical collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate the combinationof Jacobio's CD73 monoclonal antibody JAB-BX102 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

Click here to know more about our partnership.

Cutting-edge therapy partners

Using the latest research to bring hope to patients

Click here to know more about our partnership.

Artificial intelligence partners

Helping with early drug discovery

CRO/CDMO collaboration partners

Collaborations in drug R&D

We look forward to working with you to advance drug development and commercialization

With an experienced business team with deep understanding of the Chinese and global markets, Jacobio has worked with many well-known international companies to foster drug development and commercialization.

In the future, we will focus on the next generation of cutting-edge technologies that can lead to breakthrough therapies for patients around the world.

If you are interested in partnering with Jacobio, please contact us at: